Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.
You may also be interested in...
Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
If approved, the osteoporosis drug may struggle to compete with Lilly’s Evista, according to PEARL data.
Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
If approved, the osteoporosis drug may struggle to compete with Lilly’s Evista, according to PEARL data.
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.